Related Experiment Video
Updated: May 25, 2026

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
Published on: May 15, 2021
Nec-1 protects against nonapoptotic cell death in cisplatin-induced kidney injury
Vivian Regina Tristão1, Paula Fernanda Gonçalves, Maria Aparecida Dalboni
1Department of Medicine, Federal University of São Paulo, São Paulo, Brazil.
Background/Aims:
Necrostatin-1 (Nec-1) inhibits necroptosis, a nonapoptotic cell death pathway. Acute kidney injury (AKI) is a clinical problem of high incidence and mortality. It involves several mechanisms of cell death. We aim to evaluate the effect of Nec-1 in the toxic kidney injury model by cisplatin.
Methods:
We analyzed the effect of Nec-1 in AKI by cisplatin in human proximal tubule cells by flow cytometry.
Results:
Our results show that Nec-1 has no effect on apoptosis in renal tubular epithelial cells (Nec-1 + Cis group 13.4 ± 1.7% vs. Cis group 14.6 ± 1.4%) (p > 0.05). But, in conditions in which apoptosis was blocked by benzyloxy-carbonyl-Val-Ala-Asp-fluoromethyl ketone (z-VAD-fmk) the use of Nec-1 completely reversed cell viability (Nec-1 + Cis + z-VAD group 72.9 ± 6.3% vs. Cis group 35.5 ± 2.2%) (p < 0.05) suggesting that Nec-1 has effect on nonapoptotic cell death (necroptosis).
Conclusion:
Our findings suggest that the combined use of apoptosis and necroptosis inhibitors can provide additional cytoprotection in AKI. Furthermore, this is the first study to demonstrate that Nec-1 inhibits tubular kidney cell death and restores cell viability via a nonapoptotic mechanism.
Insights
Necrostatin-1 (Nec-1) protects kidney cells from cisplatin injury by inhibiting necroptosis, a nonapoptotic cell death pathway. Combined inhibition of apoptosis and necroptosis offers enhanced cytoprotection in acute kidney injury (AKI).
Area of Science:
- Nephrology
- Cell Biology
- Toxicology
Background:
- Acute kidney injury (AKI) is a significant clinical challenge with high mortality.
- Multiple cell death mechanisms contribute to AKI pathogenesis.
- Necrostatin-1 (Nec-1) is known to inhibit necroptosis, a specific form of programmed cell death.
Purpose of the Study:
- To investigate the therapeutic potential of Nec-1 in a cisplatin-induced AKI model.
- To determine if Nec-1 affects apoptosis or necroptosis in renal tubular cells.
- To evaluate the combined effect of apoptosis and necroptosis inhibition in AKI.
Main Methods:
- Cisplatin was used to induce AKI in human proximal tubule cells.
- Flow cytometry was employed to analyze cell death pathways.
- Cells were treated with Nec-1 and/or benzyloxy-carbonyl-Val-Ala-Asp-fluoromethyl ketone (z-VAD-fmk) to block apoptosis.
Main Results:
- Nec-1 did not significantly alter apoptosis levels in cisplatin-treated renal tubular epithelial cells.
- In the presence of the apoptosis inhibitor z-VAD-fmk, Nec-1 significantly restored cell viability.
- These findings indicate Nec-1 specifically targets and inhibits nonapoptotic cell death, likely necroptosis.
Conclusions:
- Nec-1 effectively inhibits tubular kidney cell death through a nonapoptotic mechanism.
- The study demonstrates Nec-1's role in restoring cell viability in AKI.
- Combined inhibition of apoptosis and necroptosis presents a promising strategy for enhanced cytoprotection in AKI.
Related Concept Videos
Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become anucleated and die, but their...
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Cellular Injury IV: Necrosis
Cellular Injury V: Apoptosis and Autophagy
Acute Kidney Injury IV: Diagnostic Studies and Prevention
